Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

Study ID
NCT02834780

Study type
Interventional

Study phase
Phase 1

Study status
Active, not recruiting

Trial Acronym

Trial Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.

More informations

Trial Starting Date

Jul 31,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

128

Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

In order to facilitate the use of our website, we use cookies.